OBJECTIVES: The present study was designed to compare the absolute myocardial blood flow (MBF) after intravenous dipyridamole infusion with that during dobutamine-atropine administration in normal healthy male volunteers. BACKGROUND: Both safety and usefulness of dobutamine-atropine stress in myocardial perfusion imaging have been reported. However, no information exists on whether the magnitude ofhyperemia achieved with dipyridamole and dobutamine-atropine is comparable. METHODS: Myocardial blood flow was measured with positron emission tomography and 15O-labeled water in 20 healthy young men (23 +/- 3 years) 1) at baseline, 2) after dipyridamole infusion (0.56 mg/kg over 4 min), and 3) during dobutamine (40 microg/kg/min) and atropine (0.25 to 1.0 mg) infusion. RESULTS: The MBF was significantly increased during dipyridamole infusion and during dobutamine-atropine stress compared with at rest (4.33 +/- 1.23 and 5.89 +/- 1.58 vs. 0.67 +/- 0.16 ml/min/g, respectively, p < 0.0001). Moreover, dobutamine-atropine infusion produced greater MBF compared with dipyridamole (p = 0.0011), while coronary vascular resistance did not differ significantly after dipyridamole administration and during dobutamine-atropine infusion (17.6 +/- 7.9 vs. 18.6 +/- 5.6 mm Hg/[ml/min/g], respectively). CONCLUSIONS: Near maximal coronary vasodilatation caused by dipyridamole is attainable using dobutamine and atropine in young healthy volunteers. Dobutamine in conjunction with atropine is no less effective than dipyridamole in producing myocardial hyperemia.
OBJECTIVES: The present study was designed to compare the absolute myocardial blood flow (MBF) after intravenous dipyridamole infusion with that during dobutamine-atropine administration in normal healthy male volunteers. BACKGROUND: Both safety and usefulness of dobutamine-atropine stress in myocardial perfusion imaging have been reported. However, no information exists on whether the magnitude ofhyperemia achieved with dipyridamole and dobutamine-atropine is comparable. METHODS: Myocardial blood flow was measured with positron emission tomography and 15O-labeled water in 20 healthy young men (23 +/- 3 years) 1) at baseline, 2) after dipyridamole infusion (0.56 mg/kg over 4 min), and 3) during dobutamine (40 microg/kg/min) and atropine (0.25 to 1.0 mg) infusion. RESULTS: The MBF was significantly increased during dipyridamole infusion and during dobutamine-atropine stress compared with at rest (4.33 +/- 1.23 and 5.89 +/- 1.58 vs. 0.67 +/- 0.16 ml/min/g, respectively, p < 0.0001). Moreover, dobutamine-atropine infusion produced greater MBF compared with dipyridamole (p = 0.0011), while coronary vascular resistance did not differ significantly after dipyridamole administration and during dobutamine-atropine infusion (17.6 +/- 7.9 vs. 18.6 +/- 5.6 mm Hg/[ml/min/g], respectively). CONCLUSIONS: Near maximal coronary vasodilatation caused by dipyridamole is attainable using dobutamine and atropine in young healthy volunteers. Dobutamine in conjunction with atropine is no less effective than dipyridamole in producing myocardial hyperemia.
Authors: Abdou Elhendy; Arend F L Schinkel; Jeroen J Bax; Ron T van Domburg; Roelf Valkema; Elena Biagini; Harm H Feringa; Don Poldermans Journal: J Nucl Cardiol Date: 2006-09 Impact factor: 5.952
Authors: Abdou Elhendy; Arend F L Schinkel; Ron T van Domberg; Jeroen J Bax; Roelf Valkema; Don Poldermans Journal: Int J Cardiovasc Imaging Date: 2006-04-21 Impact factor: 2.357
Authors: Ashley M Groves; Vicky Goh; Sabarinath Rajasekharan; Irfan Kayani; Raymondo Endozo; John C Dickson; Leon J Menezes; Manu Shastry; Said B Habib; Peter J Ell; Brian F Hutton Journal: Eur Radiol Date: 2008-05-09 Impact factor: 5.315
Authors: Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett Journal: J Nucl Cardiol Date: 2018-02 Impact factor: 5.952